That is, (1) the presence of the IFN signature was shown to be a risk factor for arthritis development in preclinical disease [4], and (2) the presence of the IFN signature in established RA was found to be associated with the clinical response to treatment with rituximab [5] and tocilizumab [6]. Here, IFNA1 is linked to Arthritis.